Mutliple Sclerosis - AnaSpec Introduces New Anti-MOG (35-55) Antibody

Main Category: Multiple Sclerosis
Also Included In: Neurology / Neuroscience
Article Date: 27 Jun 2007 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:4 stars

3.78 (9 votes)

Healthcare Prof:4 and a half stars

4.33 (3 votes)


Leveraging its portfolio of MOG (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has introduced its new Rabbit Anti-MOG (35-55) antibody.

Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin superfamily, is expressed exclusively in central nervous system myelin. Recent studies suggest that MOG may function in the completion, compaction, and maintenance of myelin in the central nervous system.1 Even though MOG physiological function is not entirely understood, studies have correlated the immune response of MOG to autoimmune mediated demyelination in several species.2 MOG is able to induce encephalitogenic T cell response, autoantibody response, and produce relapsing-remitting neurological disease with an extensive plaque-like demyelination.3 The autoantibody response to MOG [anti-MOG protein and anti-MOG (35-55) peptide] has been seen in MS patients and EAE-induced mice. This phenomenon suggests that MOG may have an important role in the development of MS and EAE, an experimental in vivo animal model for MS.4,5

Rabbit anti-MOG (35-55) polyclonal antibody was raised against a synthetic peptide from the N-terminus corresponding to amino acids 35-55 of mouse and rat MOG. There is only one amino acid residue difference between the mouse/rat and human MOG (35-55) peptide. ELISA results show that Anti-MOG (35-55) cross-react with human. The antibodies were also evaluated by Western blot.

For more information, visit this link.

AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry. Established in 1993, AnaSpec's ISO9001:2000 certified headquarters and manufacturing facilities are located in San Jose, CA.

http://www.anaspec.com

Article adapted by Medical News Today from original press release.
Visit our multiple sclerosis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Ping Yang. "Mutliple Sclerosis - AnaSpec Introduces New Anti-MOG (35-55) Antibody." Medical News Today. MediLexicon, Intl., 27 Jun. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/75274.php>

APA
Ping Yang. (2007, June 27). "Mutliple Sclerosis - AnaSpec Introduces New Anti-MOG (35-55) Antibody." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/75274.php.

Please note: If no author information is provided, the source is cited instead.




Multiple Sclerosis

Most Popular Articles



Follow Our Multiple Sclerosis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Multiple Sclerosis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »